GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
10 Aug 2018 03:00 PM
RNS
Director/PDMR Shareholding
08 Aug 2018 12:35 PM
RNS
Director/PDMR Shareholding
07 Aug 2018 07:00 AM
RNS
Iain Mackay appointed GSK Chief Financial Officer
02 Aug 2018 11:04 AM
RNS
Total Voting Rights
31 Jul 2018 05:03 PM
RNS
Director/PDMR Shareholding
31 Jul 2018 04:37 PM
RNS
Director/PDMR Shareholding
27 Jul 2018 04:30 PM
RNS
Director/PDMR Shareholding
27 Jul 2018 02:47 PM
RNS
CHMP recommend Nucala for severe asthma children
26 Jul 2018 07:00 AM
RNS
GSK reports on FDA Ad Com on mepolizumab for COPD
25 Jul 2018 04:15 PM
RNS
Director/PDMR Shareholding
25 Jul 2018 11:00 AM
RNS
GSK and 23andMe Agreement
25 Jul 2018 11:00 AM
RNS
2nd Quarter Results
24 Jul 2018 09:01 AM
RNS
ViiV announces Juluca 100 week data at AIDS 2018
24 Jul 2018 09:00 AM
RNS
ViiV shows positive phIII data on two-drug combo
19 Jul 2018 04:45 PM
RNS
Director/PDMR Shareholding
17 Jul 2018 05:46 PM
RNS
Director/PDMR Shareholding
17 Jul 2018 04:54 PM
RNS
Director/PDMR Shareholding
17 Jul 2018 04:49 PM
RNS
Director/PDMR Shareholding
16 Jul 2018 02:51 PM
RNS
Director/PDMR Shareholding
16 Jul 2018 11:11 AM
RNS
Director/PDMR Shareholding
13 Jul 2018 04:16 PM
RNS
Director/PDMR Shareholding
13 Jul 2018 04:16 PM
RNS
Director/PDMR Shareholding
11 Jul 2018 02:42 PM
RNS
Director/PDMR Shareholding
02 Jul 2018 02:30 PM
RNS
Total Voting Rights
14 Jun 2018 07:00 AM
RNS
Positive headline results for ViiV GEMINI studies
12 Jun 2018 05:15 PM
RNS
Director/PDMR Shareholding
12 Jun 2018 02:00 PM
RNS
GSK announces changes to Corporate Executive Team
01 Jun 2018 01:00 PM
RNS
GSK completes Consumer Healthcare buyout
01 Jun 2018 09:42 AM
RNS
Total Voting Rights
29 May 2018 07:00 AM
RNS
GSK Once-daily single inhaler triple therapy COPD
21 May 2018 11:02 AM
RNS
ViiV granted EU marketing authorisation for Juluca
15 May 2018 01:39 PM
RNS
Director/PDMR Shareholding
11 May 2018 03:17 PM
RNS
Director/PDMR Shareholding
10 May 2018 05:20 PM
RNS
Block listing Interim Review
09 May 2018 05:05 PM
RNS
Director/PDMR Shareholding - replacement
09 May 2018 12:00 PM
RNS
Directorate Change
03 May 2018 06:31 PM
RNS
Result of General Meeting
03 May 2018 06:29 PM
RNS
Result of AGM
01 May 2018 02:45 PM
RNS
Total Voting Rights
27 Apr 2018 12:43 PM
RNS
Director/PDMR Shareholding
26 Apr 2018 03:30 PM
RNS
Director/PDMR Shareholding
25 Apr 2018 12:07 PM
RNS
Second Price Monitoring Extn
25 Apr 2018 12:02 PM
RNS
Price Monitoring Extension
25 Apr 2018 12:00 PM
RNS
1st Quarter Results
24 Apr 2018 05:41 PM
RNS
Trelegy Ellipta expanded US COPD indication
20 Apr 2018 03:15 PM
RNS
Director/PDMR Shareholding
20 Apr 2018 03:15 PM
RNS
Director/PDMR Shareholding
19 Apr 2018 07:00 AM
RNS
IMPACT study shows benefits of Trelegy Ellipta
18 Apr 2018 10:34 AM
RNS
Landmark IMPACT study to be published in NEJM
18 Apr 2018 10:02 AM
RNS
IMPACT study shows benefits of Trelegy Ellipta

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

UK 100

Latest directors dealings